PHARMACOKINETIC ANALYSIS OF AZELAIC ACID DISODIUM SALT - A PROPOSED SUBSTRATE FOR TOTAL PARENTERAL-NUTRITION

被引:27
作者
BERTUZZI, A
GANDOLFI, A
SALINARI, S
MINGRONE, G
ARCIERIMASTROMATTEI, E
FINOTTI, E
GRECO, AV
机构
[1] UNIV ROME LA SAPIENZA, DIPARTIMENTO INFORMAT & SISTEMIST, I-00185 ROME, ITALY
[2] UNIV CATTOLICA SACRO CUORE, IST CLIN MED, I-00168 ROME, ITALY
关键词
D O I
10.2165/00003088-199120050-00005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Azelaic acid was the first dicarboxylic acid proposed as an alternative energy substrate in total parenteral nutrition. In this study, the pharmacokinetics of azelaic acid were investigated in 12 healthy volunteers, 7 receiving a constant infusion (10g over 90 min) and 5 a bolus dose (1g). The 24h urinary excretion and plasma concentration in blood samples taken at regular intervals were assayed by gas-liquid chromatography. Experimental data were analysed by a 2-compartment nonlinear model that describes both tubular secretion and cellular uptake in Michaelis-Menten terms. A high value of urinary excretion (mean 76.9% of infused dose) and a mean clearance of 8.42 L/h were found, suggesting the presence of tubular secretion. Estimating the population mean of the pharmacokinetic model parameters gave a maximal cellular uptake of 0.657 g/h. The model predicts that 90% of the maximal uptake should be reached in the plateau phase of a constant infusion of 2.2 g/h. The presence of extensive and rapid losses through urinary excretion, and the low estimated value of the maximal cellular uptake, indicate that azelaic acid is not suitable as an energy substrate for total parenteral nutrition.
引用
收藏
页码:411 / 419
页数:9
相关论文
共 28 条
[1]   INFLUENCE OF TOTAL PARENTERAL-NUTRITION ON FUEL UTILIZATION IN INJURY AND SEPSIS [J].
ASKANAZI, J ;
CARPENTIER, YA ;
ELWYN, DH ;
NORDENSTROM, J ;
JEEVANANDAM, M ;
ROSENBAUM, SH ;
GUMP, FE ;
KINNEY, JM .
ANNALS OF SURGERY, 1980, 191 (01) :40-46
[2]  
BEAL SL, 1985, NONMEM USERS GUIDE
[3]  
BISCHOFF KB, 1975, CANCER CHEMOTH REP 1, V59, P777
[4]  
BOHMER T, 1977, LANCET, V1, P127
[5]  
Carson E R, 1983, MATH MODELING METABO
[6]  
CHAMBERS JM, 1973, BIOMETRIKA, V60, P1
[7]   POPULATION PHARMACOKINETIC ANALYSIS OF BISOPROLOL [J].
GREVEL, J ;
THOMAS, P ;
WHITING, B .
CLINICAL PHARMACOKINETICS, 1989, 17 (01) :53-63
[8]   SYNDROME OF SYSTEMIC CARNITINE DEFICIENCY - CLINICAL, MORPHOLOGIC, BIOCHEMICAL, AND PATHOPHYSIOLOGIC FEATURES [J].
KARPATI, G ;
CARPENTER, S ;
ENGEL, AG ;
WATTERS, G ;
ALLEN, J ;
ROTHMAN, S ;
KLASSEN, G ;
MAMER, OA .
NEUROLOGY, 1975, 25 (01) :16-24
[9]  
Kshirsagar A. K., 1972, MULTIVARIATE ANAL
[10]  
MCGARRY JD, 1971, J BIOL CHEM, V246, P6247